Author Archives: Alice Melao

Sangamo Therapeutics is preparing to launch a Phase 1/2 clinical study in the United Kingdom to explore the potential of its cell-based CAR-Treg therapy — TX200 — in preventing immune-mediated rejection of transplanted kidneys in patients with end-stage renal disease. The U.K.’s Medicines Healthcare Products Regulatory…

Treatment of atypical hemolytic uremic syndrome (aHUS) with Soliris (eculizumab) should be maintained even after clinical deterioration, a case report suggests. This is the first report of suboptimal response to Soliris in a patient with aHUS associated with mutations in both the CFI and THBD genes, the…

Clinical features and outcomes of patients with anti-factor H antibody, associated with atypical hemolytic uremic syndrome (aHUS), were reported in a nationwide study conducted by Indian researchers. The study, “Clinical and Immunological Profile of Anti-factor H Antibody Associated Atypical Hemolytic Uremic Syndrome: A Nationwide Database,” was published…

Treatment with Soliris (eculizumab, sold by Alexion) for recurrent atypical hemolytic uremic syndrome (aHUS) can result in the accumulation of antibodies in the kidneys, a rare case suggests. The case was described in the study “Monoclonal IgG4/2κ Deposition Following Eculizumab Therapy for Recurrent Atypical Hemolytic…

A novel genetic variant of the CFH gene, which encodes an important protein from the immune complement system, was linked to the development of atypical hemolytic uremic syndrome (aHUS) in a German woman. Her case was reported in a study, “…

A rare case of atypical hemolytic uremic syndrome (aHUS) manifesting in generalized seizures in a 14-month-old girl highlights the importance of prompt diagnosis and treatment to ensure better outcomes for this young population, a report says. The case was described in a study, “…

Omeros Corporation’s lead therapy candidate, OMS721, being developed for the treatment of complement- and inflammation-related disorders including atypical hemolytic uremic syndrome (aHUS), will now be known as narsoplimab, the company announced. The generic name narsoplimab was approved by the United States Adopted Names (USAN) Council in consultation…

Interval treatment with Soliris (eculizumab) may have a steady and prolonged effect in treating people with atypical hemolytic uremic syndrome (aHUS) with limited access to the costly drug, a case report suggests. Further studies focused on defining the best dose and regimen are still required, researchers said.

Treatment with Soliris (eculizumab) is an effective strategy to manage atypical hemolytic uremic syndrome (aHUS) even when manifested with atypical neurological symptoms, a rare case reported by Turkish researchers suggests. The case was described in the study, “An adult case of atypical hemolytic uremic syndrome…

Omeros Corporation, in collaboration with the University of Cambridge, has established a new research center that will focus on the development of therapies for complement- and inflammation-related disorders, including atypical hemolytic uremic syndrome (aHUS). One of the main aims of the Omeros Center at Cambridge for Complement…